The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).

Author: DixonR, GillotinC G, LaytonG, PeckR W, PosnerJ, SeaberE J, WeatherleyB C

Paper Details 
Original Abstract of the Article :
Zolmitriptan (Zomig, formerly known as 311C90), a selective 5HT1B/1D agonist is under development as an acute oral treatment for migraine. Despite the use of prophylactic medication, such as propranolol, breakthrough attacks often occur in patients. Consequently we investigated the effects of propra...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1046/j.1365-2125.1997.t01-1-00632.x

データ提供:米国国立医学図書館(NLM)

The Interplay of Propranolol and Zolmitriptan: Navigating Migraine Treatment

Migraine, a debilitating headache disorder, can be a relentless desert storm, leaving sufferers feeling lost and overwhelmed. This research explores the interaction between propranolol, a common migraine prophylactic medication, and zolmitriptan, a new antimigraine agent. The study investigates the potential effects of propranolol on the pharmacokinetics and cardiovascular responses to zolmitriptan.

Propranolol and Zolmitriptan: A Complex Desert Landscape

The findings revealed that propranolol did not significantly alter the pharmacokinetics of zolmitriptan, indicating that the two medications can be used together without affecting their absorption or elimination. However, the study also found that propranolol enhanced the cardiovascular responses to zolmitriptan, suggesting that caution is needed when co-administering these medications. It's like navigating a complex desert landscape, where the presence of one element can alter the impact of another.

Navigating Migraine Treatment with Caution

This research highlights the importance of careful monitoring when co-administering propranolol and zolmitriptan. The study underscores the need for healthcare professionals to be aware of the potential for enhanced cardiovascular effects and to adjust treatment strategies as needed to ensure patient safety. It's a reminder that managing migraine requires a comprehensive approach, carefully considering the interplay of different medications and their potential interactions.

Dr.Camel's Conclusion

This research sheds light on the complex interplay between propranolol and zolmitriptan in migraine treatment. It highlights the importance of careful monitoring and individualized treatment strategies to ensure patient safety and optimize therapeutic outcomes.

Date :
  1. Date Completed 1998-02-11
  2. Date Revised 2019-05-12
Further Info :

Pubmed ID

9431839

DOI: Digital Object Identifier

10.1046/j.1365-2125.1997.t01-1-00632.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.